A Rare Case of Pembrolizumab-Induced Reactivation of Hepatitis B

A Rare Case of Pembrolizumab-Induced Reactivation of Hepatitis B

Hepatitis B virus (HBV) infection is common across the world, especially in Asia, Africa, Southern Europe, and Latin America. The association of HBV infection in patients suffering from different oncological conditions is well established. Many cases of HBV reactivation have been reported in patient...

Full description

Bibliographic Details
Main Authors: Anita Pandey, Susan Ezemenari, Maksim Liaukovich, Ivan Richard, Avezbakiyev Boris
Format: Article
Language:English
Published: Hindawi Limited 2018-01-01
Series:Case Reports in Oncological Medicine
Online Access:http://dx.doi.org/10.1155/2018/5985131
id doaj-55f7ebf0ee6a4cc9a256728e206cd918
record_format Article
spelling doaj-55f7ebf0ee6a4cc9a256728e206cd9182020-11-25T00:47:01ZengHindawi LimitedCase Reports in Oncological Medicine2090-67062090-67142018-01-01201810.1155/2018/59851315985131A Rare Case of Pembrolizumab-Induced Reactivation of Hepatitis BAnita Pandey0Susan Ezemenari1Maksim Liaukovich2Ivan Richard3Avezbakiyev Boris4Department of Hematology and Oncology, Brookdale University Hospital, Medical Center, Brooklyn, USADepartment of Hematology and Oncology, Brookdale University Hospital, Medical Center, Brooklyn, USADepartment of Hematology and Oncology, Brookdale University Hospital, Medical Center, Brooklyn, USADepartment of Hematology and Oncology, Brookdale University Hospital, Medical Center, Brooklyn, USADepartment of Hematology and Oncology, Brookdale University Hospital, Medical Center, Brooklyn, USAHepatitis B virus (HBV) infection is common across the world, especially in Asia, Africa, Southern Europe, and Latin America. The association of HBV infection in patients suffering from different oncological conditions is well established. Many cases of HBV reactivation have been reported in patients on immunosuppressive chemotherapy and in patients undergoing hematopoietic bone marrow transplantations. Only one case has been reported so far of HBV reactivation in a patient treated with programmed cell death receptor 1 (PD-1) checkpoint inhibitors in the setting of HIV status. We report a case of a 51-year-old male, former smoker, diagnosed with stage IV poorly differentiated adenocarcinoma of the lung, and started on pembrolizumab, who developed reactivation of chronic hepatitis requiring antiviral therapy.http://dx.doi.org/10.1155/2018/5985131
collection DOAJ
language English
format Article
sources DOAJ
author Anita Pandey
Susan Ezemenari
Maksim Liaukovich
Ivan Richard
Avezbakiyev Boris
spellingShingle Anita Pandey
Susan Ezemenari
Maksim Liaukovich
Ivan Richard
Avezbakiyev Boris
A Rare Case of Pembrolizumab-Induced Reactivation of Hepatitis B
Case Reports in Oncological Medicine
author_facet Anita Pandey
Susan Ezemenari
Maksim Liaukovich
Ivan Richard
Avezbakiyev Boris
author_sort Anita Pandey
title A Rare Case of Pembrolizumab-Induced Reactivation of Hepatitis B
title_short A Rare Case of Pembrolizumab-Induced Reactivation of Hepatitis B
title_full A Rare Case of Pembrolizumab-Induced Reactivation of Hepatitis B
title_fullStr A Rare Case of Pembrolizumab-Induced Reactivation of Hepatitis B
title_full_unstemmed A Rare Case of Pembrolizumab-Induced Reactivation of Hepatitis B
title_sort rare case of pembrolizumab-induced reactivation of hepatitis b
publisher Hindawi Limited
series Case Reports in Oncological Medicine
issn 2090-6706
2090-6714
publishDate 2018-01-01
description Hepatitis B virus (HBV) infection is common across the world, especially in Asia, Africa, Southern Europe, and Latin America. The association of HBV infection in patients suffering from different oncological conditions is well established. Many cases of HBV reactivation have been reported in patients on immunosuppressive chemotherapy and in patients undergoing hematopoietic bone marrow transplantations. Only one case has been reported so far of HBV reactivation in a patient treated with programmed cell death receptor 1 (PD-1) checkpoint inhibitors in the setting of HIV status. We report a case of a 51-year-old male, former smoker, diagnosed with stage IV poorly differentiated adenocarcinoma of the lung, and started on pembrolizumab, who developed reactivation of chronic hepatitis requiring antiviral therapy.
url http://dx.doi.org/10.1155/2018/5985131
work_keys_str_mv AT anitapandey ararecaseofpembrolizumabinducedreactivationofhepatitisb
AT susanezemenari ararecaseofpembrolizumabinducedreactivationofhepatitisb
AT maksimliaukovich ararecaseofpembrolizumabinducedreactivationofhepatitisb
AT ivanrichard ararecaseofpembrolizumabinducedreactivationofhepatitisb
AT avezbakiyevboris ararecaseofpembrolizumabinducedreactivationofhepatitisb
AT anitapandey rarecaseofpembrolizumabinducedreactivationofhepatitisb
AT susanezemenari rarecaseofpembrolizumabinducedreactivationofhepatitisb
AT maksimliaukovich rarecaseofpembrolizumabinducedreactivationofhepatitisb
AT ivanrichard rarecaseofpembrolizumabinducedreactivationofhepatitisb
AT avezbakiyevboris rarecaseofpembrolizumabinducedreactivationofhepatitisb
_version_ 1725262529822720000

Similar Items